During #LBDAwarenessMonth be sure to check out the Phase 2 SHIMMER trial - Cognition Therapeutics, Inc. partnered with experts at the LBDA & the University of Miami Miller School of Medicine to design the study, which has enrolled 130 patients with mild-to-moderate DLB at centers of excellence across the US. Topline results, which are anticipated later this year, are expected to provide insights into this patient population and the potential therapeutic impact of CT1812 on the constellation of symptoms that affect DLB patients. Learn more about our #clinicaltrials here https://lnkd.in/eFCAdmwD #Dementia #LewyBodyDementia #biotech
Cognition Therapeutics, Inc. Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia #StrongerTogether #LBDAwareness #dementia #LewyBodyDementia #biotech https://lnkd.in/e5_VCd_U